false
OasisLMS
Catalog
SCCM Resource Library
Subphenotypes in ARDS: Is It Time for Personalized ...
Subphenotypes in ARDS: Is It Time for Personalized Medicine, Including for COVID-19 Patients?
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this talk, Dr. Kathleen Liu discusses the concept of subphenotypes in acute respiratory distress syndrome (ARDS) and whether personalized medicine, including for COVID-19 patients, is necessary. She explains that phenotyping refers to categorizing patients into subgroups based on specific characteristics or features. Different ways to phenotype ARDS have been discussed for decades, including risk factors, severity, radiographic patterns, and COVID-19 versus typical ARDS. The goal of phenotyping is to find groups of patients that respond differently to therapies in order to improve outcomes. Dr. Liu describes the challenges and variability in using clinically obvious phenotypes and explores the potential of identifying hidden or latent phenotypes using biomarkers and machine learning approaches. She presents research findings on the hyperinflammatory phenotype and its association with worse outcomes in ARDS and COVID-19 ARDS patients. However, she emphasizes the need for prospective validation and clinical testing before implementing personalized medicine strategies for ARDS.
Asset Subtitle
Pulmonary, 2023
Asset Caption
Type: one-hour concurrent | ARDS in the Time of COVID-19 (SessionID 1198064)
Meta Tag
Content Type
Presentation
Knowledge Area
Pulmonary
Membership Level
Professional
Membership Level
Select
Tag
Acute Respiratory Distress Syndrome ARDS
Year
2023
Keywords
subphenotypes
acute respiratory distress syndrome
personalized medicine
COVID-19 patients
phenotyping
×
Please select your language
1
English